Sacubitril/Valsartan vs Enalapril in Heart Failure Due to Chagas Disease

Are guideline-recommended treatments for heart failure (HF) effective and safe in patients with Chagas disease?This trial found that in patients with heart failure with reduced ejection fraction (HFrEF) due to Chagas cardiomyopathy, sacubitril/valsartan was not significantly different from enalapril in the composite outcome of cardiovascular death or hospitalization for HF, but led to a greater reduction in N-terminal pro-B-type natriuretic peptide.In patients with HFrEF due to Chagas disease, sacubitril/valsartan did not result in better clinical outcomes.

Corresponding Author: Renato D. Lopes, MD, PhD, Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715 (renato.lopes@duke.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.